STRATA Skin Sciences, Inc. (SSKN)

STRATA Skin Sciences, Inc. is a medical technology company in Horsham, Pennsylvania, focused on devices for dermatologic conditions. Its origins trace to Electro-Optical Sciences, which was founded in 1989 and later renamed MELA Sciences while it developed the MelaFind skin cancer imaging system. The company took the STRATA Skin Sciences name in January 2016 after shifting its focus to dermatology.

The transformation came through the acquisition of the XTRAC excimer laser and VTRAC lamp businesses, which treat chronic skin conditions such as psoriasis and vitiligo. XTRAC systems are placed with dermatology practices, and the company earns recurring revenue from treatments performed on them. The second major line is sales of equipment, including systems for acne treatment such as the TheraClear device.

STRATA sold its products in the United States directly to physicians and through distributors in international markets. Its financial profile depended on the number of treatment sessions performed on installed lasers and on equipment sales, which could vary with practice budgets and the broader environment for elective procedures. The company also relied on debt financing from a specialty lender.

The stock traded on the Nasdaq Capital Market under the symbol SSKN. Like many small-capitalization healthcare companies, it faced pressure on share price and liquidity, and it had effected a reverse stock split to address listing requirements. Its management acknowledged that the costs of meeting Nasdaq listing rules and SEC reporting obligations were significant for a company of its size.

On February 19, 2026, STRATA announced that trading in its common stock on the Nasdaq Capital Market had been suspended at the opening of business and that a Form 25 had been filed with the SEC. The company said the decision was not due to financial instability, and its chief executive officer cited the burden of continued listing standards. The last regular session on Nasdaq was therefore February 18, 2026.

STRATA said it expected to file a Form 15 on or about March 2, 2026, which would suspend its periodic reporting obligations. It also said it was in discussions with its lender about loan terms suitable for a private company. The company warned that liquidity in the shares would likely decline and that holders could find it difficult to sell, and the announcement did not describe a specific over-the-counter quotation.

Because STRATA's revenue relied on treatment volumes from installed devices, the company emphasized customer service and utilization at physician practices. It was a small company with limited analyst coverage, and its shares had traded at low levels in recent years. The move to deregister places STRATA among a group of small healthcare companies that chose to exit the public markets to lower costs rather than seek a sale.